NASDAQ:FIXX - Homology Medicines Stock Price, Forecast & News

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines Inc (NASDAQ:FIXX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.09. The firm had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.38 million. Homology Medicines had a negative net margin of 4,740.81% and a negative return on equity of 43.33%. View Homology Medicines' Earnings History.

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Homology Medicines.

6 brokerages have issued 1-year price objectives for Homology Medicines' stock. Their forecasts range from $29.00 to $37.00. On average, they expect Homology Medicines' stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 114.3% from the stock's current price. View Analyst Price Targets for Homology Medicines.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Headlines about FIXX stock have trended very negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Homology Medicines earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Homology Medicines.

Homology Medicines saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,050,000 shares, an increase of 6.6% from the December 15th total of 2,860,000 shares. Based on an average trading volume of 341,000 shares, the short-interest ratio is presently 8.9 days. Approximately 10.1% of the shares of the stock are short sold. View Homology Medicines' Current Options Chain.

Some companies that are related to Homology Medicines include ArQule (ARQL), ChemoCentryx (CCXI), Karuna Therapeutics (KRTX), Amicus Therapeutics (FOLD), Ra Pharmaceuticals (RARX), Synthorx (THOR), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Heron Therapeutics (HRTX), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH), Aimmune Therapeutics (AIMT), Eidos Therapeutics (EIDX) and Endonovo Therapeutics (ENDV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Editas Medicine (EDIT), Stag Industrial (STAG), NVIDIA (NVDA), Pfizer (PFE), AT&T (T), Verizon Communications (VZ), Exxon Mobil (XOM) and Nektar Therapeutics (NKTR).

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.09%) and Alpine Global Management LLC (0.03%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly, Ventures Iv LP 5Am, Vida Ventures, Llc and W Bradford Smith. View Institutional Ownership Trends for Homology Medicines.

FIXX stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Alpine Global Management LLC. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FIXX stock can currently be purchased for approximately $15.40.

Homology Medicines has a market capitalization of $678.14 million and generates $3.68 million in revenue each year. The company earns $-57,220,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Homology Medicines employs 124 workers across the globe.View Additional Information About Homology Medicines.

The official website for Homology Medicines is http://www.homologymedicines.com/.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.